News - GlaxoSmithKline, Benlysta, Anti-Arthritics/Rheumatics

Pipeline innovation bodes well for systemic lupus erythematosus market

18-02-2014

While the systemic lupus erythematosus (SLE) treatment market is predominantly limited to GlaxoSmithKline’s…

AmgenAnti-Arthritics/RheumaticsBenlystaGlaxoSmithKlineImmuPharmaLupuzorLymphoCideMarkets & MarketingPharmaceuticalRituxanRoche

EU5 rheumatologits rate Rituxan and Benlysta for Lupus

12-08-2013

Rheumatologists in the top European nations ( EU5) countries (France, Germany, Italy, Spain, UK) give…

Anti-Arthritics/RheumaticsBenlystaBiogen IdecBristol-Myers SquibbEuropeGlaxoSmithKlineMarkets & MarketingOrenciaPharmaceuticalRituxanRoche

Epratuzumab and Lupuzor have potential to offer improvements over Benlysta in reducing Lupus disease activity

04-04-2013

US and European rheumatologists surveyed by health care advisory firm Decision Resources indicate that…

Anthera PharmaceuticalsAnti-Arthritics/RheumaticsBenlystaBiotechnologyblisibimodepratuzumabEuropeGlaxoSmithKlineImmunomedicsImmuPharmaLupuzorMarkets & MarketingNorth AmericaPharmaceuticalUCB

UK NICE agrees to reconsider decision to deny NHS access to GSK's Benlysta

07-09-2012

The UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) confirmed this…

Anti-Arthritics/RheumaticsBenlystaEuropeGlaxoSmithKlinePharmaceuticalPricingRare diseasesRegulation

Benlysta continues to penetrate lupus market one year post-launch; report

08-05-2012

More than two-thirds of surveyed rheumatologists have initiated trial of GlaxoSmithKline (LSE: GSK) and…

Anti-Arthritics/RheumaticsBenlystaBiotechnologyGlaxoSmithKlineHuman Genome SciencesMarkets & MarketingPharmaceuticalRare diseases

UK NICE gives draft "No" to Benlysta, and negative final guidance for Tyverb and Herceptin

27-04-2012

There was a batch of bad news emanating from the US drugs watchdog the National Institute for Health…

Anti-Arthritics/RheumaticsBenlystaEuropeGlaxoSmithKlineHerceptinOncologyPharmaceuticalPricingRare diseasesRegulationRocheTyverb

Thought leaders indicate Benlysta has advantages over market leader CellCept for Lupus

26-04-2012

Surveyed US rheumatologists and managed care organization (MCO) pharmacy directors agree that reducing…

Anti-Arthritics/RheumaticsBenlystaCellCeptEli LillyforigerimodGlaxoSmithKlineHuman Genome SciencesImmuPharmaMarkets & MarketingNorth AmericaPharmaceuticalRare diseasesRocheSymBio Pharmaceuticalstabalumab

Benlysta gaining bigger US market share

13-12-2011

Over half of surveyed US rheumatologists surveyed by Decision Resources unit BioTrends have initiated…

Anti-Arthritics/RheumaticsBenlystaBiotechnologyGlaxoSmithKlineHuman Genome SciencesMarkets & MarketingNorth AmericaPharmaceuticalRare diseases

Systemic lupus erythematosus drug market to grow to $1.6 billion in 2018

10-11-2011

The global systemic lupus erythematosus (SLE) therapeutics market in the seven leading countries ( the…

Anti-Arthritics/RheumaticsBenlystaGlaxoSmithKlineGlobalHuman Genome SciencesMarkets & MarketingPharmaceutical

Benlysta to drive lupus drug market to $2.1 billion in 2020

26-10-2011

Driven primarily by the launch and uptake of Human Genome Sciences (Nasdaq: HGSI) and GlaxoSmithKline’s…

Anti-Arthritics/RheumaticsBenlystaGlaxoSmithKlineMarkets & MarketingPharmaceuticalRare diseases

Benlysta heading in right direction, but uptake slower than originally expected, says BioTrends

07-08-2011

Rheumatologists are maintaining enthusiasm for Human Genome Sciences (Nasdaq: HGSI) and GlaxoSmithKline’s…

Anti-Arthritics/RheumaticsBenlystaGlaxoSmithKlineHuman Genome SciencesMarkets & MarketingPharmaceutical

Back to top